David Tepper
Appaloosa Management
David Tepper SPDR S&P Biotech ETF stake
total: 317
Appaloosa Management XBI trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2017 Q2
- Held for:
- 1 quarter
- Latest activity:
- 2017 Q3
According to 2026 Q2 report, David Tepper doesn't hold any SPDR S&P Biotech ETF (XBI) shares. To date, the estimated cost basis is nearly $77.18 for "buy" trades and estimated average "sell" price is $77.18. Appaloosa Management first purchased XBI in 2017 Q2, initially acquiring 330,000 shares. Since the initial investment in SPDR S&P Biotech ETF (XBI), Appaloosa Management has made 1 more transaction.
When did David Tepper sell SPDR S&P Biotech ETF (XBI)?
David Tepper sold off the entire SPDR S&P Biotech ETF (XBI) position in 2017 Q3.
When did David Tepper buy SPDR S&P Biotech ETF (XBI)?
David Tepper first invested in SPDR S&P Biotech ETF (XBI) in 2017 Q2 at the reported quarter-end price of $77.18 per share.
What's the cost basis of Appaloosa Management's XBI stake?
The estimated cost basis for SPDR S&P Biotech ETF (XBI) stake is around $77.18 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $77.18
- Weighted AVG sell price:
- $77.18
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.